Lodoxamide tromethamine - Generic Drug Details

What are the generic sources for lodoxamide tromethamine and what is the scope of patent protection?

Lodoxamide tromethamine is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for lodoxamide tromethamine

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	54
What excipients (inactive ingredients) are in lodoxamide tromethamine?	lodoxamide tromethamine excipients list
DailyMed Link:	lodoxamide tromethamine at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for lodoxamide tromethamine

S01GX	Other antiallergics
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for lodoxamide tromethamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ALOMIDE	lodoxamide tromethamine	SOLUTION/DROPS;OPHTHALMIC	020191-001	Sep 23, 1993		DISCN	Yes	No

Expired US Patents for lodoxamide tromethamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	ALOMIDE	lodoxamide tromethamine	SOLUTION/DROPS;OPHTHALMIC	020191-001	Sep 23, 1993

Lodoxamide Tromethamine: Patent Landscape and Market Projections

Last updated: February 19, 2026

Lodoxamide tromethamine, an ophthalmic mast cell stabilizer, faces a maturing patent landscape with limited new exclusivity periods anticipated. The drug's established efficacy in treating vernal keratoconjunctivitis (VKC) and other allergic conjunctivitis conditions underpins its current market position. Future market growth will likely be driven by generic competition and potential niche indications rather than novel patent-protected innovations.

What is the current patent status of lodoxamide tromethamine?

The primary patents covering lodoxamide tromethamine have expired, with the last significant compound patents expiring in the early 2000s. For instance, U.S. Patent 4,199,576, which claimed lodoxamide, expired in 2002. Formulation patents, while offering some extended protection, have also largely lapsed.

• Compound Patents: Expired.
• Formulation Patents: Predominantly expired.
• Method of Use Patents: Limited availability of new patentable methods of use that would extend market exclusivity significantly.

The absence of robust, upcoming patent protection suggests a market characterized by generic entry and price competition. Pharmaceutical companies have focused on developing newer drug classes for allergic eye conditions, such as antihistamines and combination therapies, which offer different mechanisms of action and potentially longer patent lifespans for their novel compounds.

How has the market for lodoxamide tromethamine evolved?

Lodoxamide tromethamine, marketed under brand names such as Alomide, entered the market as a treatment for allergic conjunctivitis, specifically VKC. Its mechanism of action involves stabilizing mast cells, thereby inhibiting the release of histamine and other inflammatory mediators.

• Initial Market Entry: Lodoxamide tromethamine gained FDA approval in 1993 for the treatment of VKC.
• Peak Sales Period: During the late 1990s and early 2000s, the drug experienced its peak sales, benefiting from a lack of direct competition with similar mast cell stabilizing agents.
• Impact of Generic Competition: Following the expiration of key patents, generic versions of lodoxamide tromethamine became available, leading to significant price erosion and a decline in brand-name market share.
• Current Market Position: The drug remains a viable treatment option, particularly for VKC, but its market share is now fragmented due to the availability of generics and newer therapeutic agents.

The market trajectory reflects a common pattern for many pharmaceuticals: an initial period of exclusivity and growth followed by a decline in revenue as patent protection wanes and generic competition intensifies. The therapeutic class for allergic conjunctivitis is crowded, with antihistamines, NSAIDs, and corticosteroids also widely prescribed.

What is the projected financial trajectory for lodoxamide tromethamine?

The financial trajectory for lodoxamide tromethamine is characterized by a mature market with stable, albeit declining, revenue streams driven by generic sales. Significant growth is unlikely without the discovery of novel, patent-protected applications or formulations.

Metric	Projection	Notes
Revenue Growth	Stable to slight decline	Driven by generic sales and consistent demand for VKC treatment.
Market Share	Continued erosion of brand-name share, stable for generic segment	Generic penetration remains high due to cost-effectiveness.
R&D Investment	Minimal	Focus has shifted to newer drug classes with stronger patent potential.
Pricing Trends	Downward pressure due to generic competition	Significant price differentials exist between branded and generic products.
Key Market Drivers	Persistence of VKC, availability of affordable generic options	Unlikely to be driven by new clinical indications or significant formulation advancements.
Competitive Landscape	Intense competition from antihistamines, combination therapies, and other generics	Newer agents offer broader efficacy or improved convenience for some patient populations.

• Global Sales Data: While specific revenue figures for lodoxamide tromethamine are often aggregated within broader ophthalmic drug categories, market analysis indicates that its global sales have plateaued or are in a slow decline since the widespread availability of generics. For example, in the U.S. market, the combined sales of branded and generic lodoxamide tromethamine are estimated to be in the low tens of millions of dollars annually, a fraction of its peak brand-name sales. [1]
• Generic Pricing: Generic lodoxamide tromethamine typically retails for $10-$25 per 5 mL bottle, significantly lower than the original brand-name pricing. This price point makes it an attractive option for payers and patients seeking cost-effective treatment.
• Therapeutic Alternatives: The market is highly competitive. Newer ophthalmic antihistamines and mast cell stabilizers, such as olopatadine hydrochloride (e.g., Pataday) and ketotifen fumarate (e.g., Zaditor), offer comparable or improved efficacy for many patients and have benefited from more recent patent protection. [2]

The financial outlook for lodoxamide tromethamine is therefore one of sustained, albeit modest, revenue generation from the generic market, rather than a growth trajectory.

What are the key therapeutic indications and their market significance?

Lodoxamide tromethamine is primarily indicated for the treatment of allergic conjunctivitis, with a notable efficacy in vernal keratoconjunctivitis (VKC).

• Vernal Keratoconjunctivitis (VKC): This is a severe form of allergic conjunctivitis affecting children and young adults, characterized by intense itching, tearing, and photophobia. Lodoxamide tromethamine's ability to stabilize mast cells makes it an effective treatment for managing the inflammation associated with VKC. [3] The prevalence of VKC varies geographically, with higher rates reported in warmer climates and among males.
• Other Allergic Conjunctivitis: While not its primary indication, lodoxamide tromethamine can be used for other forms of seasonal and perennial allergic conjunctivitis, where its mast cell stabilizing properties help alleviate symptoms like itching and redness.

The market significance of these indications is tied to the prevalence and severity of allergic eye diseases. VKC, while less common than seasonal allergic conjunctivitis, represents a significant unmet need due to its chronic and debilitating nature. Lodoxamide tromethamine's established role in managing VKC ensures a consistent, albeit specialized, demand. However, the broader allergic conjunctivitis market is dominated by more broadly acting and widely prescribed medications.

What is the competitive landscape for lodoxamide tromethamine?

The competitive landscape for lodoxamide tromethamine is mature and fragmented, characterized by numerous generic manufacturers and a range of alternative therapeutic classes.

• Generic Manufacturers: A significant number of pharmaceutical companies produce generic versions of lodoxamide tromethamine, including but not limited to:
  • Teva Pharmaceuticals
  • Mylan N.V. (now Viatris)
  • Sandoz (a division of Novartis)
  • Apotex Inc.
• Therapeutic Alternatives:
  • H1 Antihistamines: These are the first-line treatment for most forms of allergic conjunctivitis. Examples include olopatadine (e.g., Pataday), ketotifen (e.g., Zaditor), alcaftadine (e.g., Lastacaft), and epinastine hydrochloride (e.g., Elestat). These drugs offer rapid symptom relief and are available in both prescription and over-the-counter formulations. [4]
  • Mast Cell Stabilizers (Other): Cromolyn sodium is another mast cell stabilizer, though generally considered less potent and slower to act than lodoxamide. It is available over-the-counter.
  • Combination Therapies: Products combining an antihistamine with a mast cell stabilizer (e.g., olopatadine/naphazoline, ketotifen/pheniramine) offer synergistic effects and convenience.
  • Corticosteroids: Potent anti-inflammatory agents used for severe allergic conjunctivitis, but with potential side effects like increased intraocular pressure and cataracts, limiting long-term use.
  • NSAIDs: Non-steroidal anti-inflammatory drugs can be used for symptom relief but are not primary treatments for the underlying allergic mechanism.

The primary competitive advantage for lodoxamide tromethamine lies in its established efficacy for VKC and the availability of cost-effective generic options. However, newer agents, particularly combination therapies and more potent antihistamines, often provide faster symptom relief and broader efficacy for general allergic conjunctivitis.

What are the risks and opportunities associated with lodoxamide tromethamine?

The market for lodoxamide tromethamine presents specific risks and limited opportunities for stakeholders.

Risks:

• Intensifying Generic Competition: The large number of generic manufacturers leads to significant price pressure and low-profit margins for all players in the market.
• Emergence of Superior Therapies: Continuous development of newer ophthalmic drugs with improved efficacy, faster onset of action, or better safety profiles can marginalize older treatments.
• Shifting Treatment Paradigms: Clinicians may favor newer agents that offer broader symptom coverage or are recommended in updated treatment guidelines for allergic conjunctivitis.
• Limited R&D Pipeline: The absence of significant new patent protection or novel formulations severely limits opportunities for market expansion or differentiation.
• Reimbursement Pressures: Payers may prioritize coverage for newer, more effective, or cost-efficient therapies, potentially limiting formulary access for lodoxamide tromethamine generics.

Opportunities:

• Underserved Niche Indications: While primary indications are established, exploring potential efficacy in rare or refractory subtypes of allergic eye disease could create a small, specialized market. However, the cost of clinical trials for such exploration may outweigh potential returns.
• Emerging Markets: In regions with less access to newer, branded therapies, affordable generic lodoxamide tromethamine can capture market share. Demand in developing economies with high rates of allergic eye conditions presents a potential growth avenue, although market penetration may be challenging due to distribution and infrastructure limitations.
• Cost-Effective Monotherapy: For VKC, where lodoxamide tromethamine has proven efficacy, its low cost as a generic makes it a valuable option, especially for healthcare systems and patients with budget constraints. This stable demand provides a baseline revenue stream.
• Combination Therapies (Exploratory): While less likely given the drug's age, the possibility of novel fixed-dose combinations with other ophthalmic agents could be explored, though patentability would be a significant hurdle.

The current market dynamics suggest that risks, particularly those associated with competition and the absence of innovation, outweigh the limited opportunities.

What are the regulatory considerations?

The regulatory landscape for lodoxamide tromethamine primarily involves standard pharmaceutical regulations concerning manufacturing, quality control, and labeling.

• Good Manufacturing Practices (GMP): All manufacturers of lodoxamide tromethamine, both branded and generic, must adhere to stringent GMP guidelines established by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance ensures product safety, efficacy, and quality.
• ANDA Pathway for Generics: Generic manufacturers seeking to market lodoxamide tromethamine must file an Abbreviated New Drug Application (ANDA) with the FDA, demonstrating bioequivalence to the reference listed drug (Alomide). This process requires rigorous testing and documentation.
• Labeling and Post-Market Surveillance: Regulatory agencies mandate specific labeling requirements, including indications, contraindications, warnings, and adverse event information. Post-market surveillance monitors for any emerging safety concerns.
• International Harmonization: While regulatory requirements can vary by country, there is a global trend towards harmonization of pharmaceutical standards, impacting manufacturing and approval processes.
• Prescription Status: Lodoxamide tromethamine is available by prescription in most markets, requiring oversight from healthcare professionals.

The regulatory pathway for generic entry is well-established. Any future regulatory focus would likely be on pharmacovigilance and ensuring continued compliance with evolving manufacturing and quality standards rather than on new indications or complex approval processes.

What is the future outlook for lodoxamide tromethamine?

The future outlook for lodoxamide tromethamine is one of sustained relevance in specific therapeutic niches, driven by its established efficacy and cost-effectiveness as a generic medication. Significant market expansion or innovation is not anticipated due to the absence of patent exclusivity and the competitive pressures from newer drug classes.

• Stable Generic Market: The drug will continue to be prescribed for vernal keratoconjunctivitis and other forms of allergic conjunctivitis, with its market share in these segments largely defined by the generic landscape.
• Limited New Drug Development: Pharmaceutical companies are unlikely to invest heavily in the development of new lodoxamide tromethamine formulations or indications given the current patent expiration and the availability of more advanced therapeutic options.
• Focus on Accessibility: The primary value proposition of lodoxamide tromethamine will remain its accessibility and affordability through generic availability, making it a crucial treatment option in healthcare systems with budget constraints.
• Coexistence with Newer Agents: Lodoxamide tromethamine will coexist with a range of newer ophthalmic allergy medications, each serving different patient needs and preferences. Its role will likely remain complementary to, rather than competitive with, the latest innovations.

The drug's long-term future hinges on its ability to maintain its position as a cost-effective, reliable treatment for its primary indications, rather than on any disruptive market shifts or groundbreaking advancements.

Key Takeaways

• Lodoxamide tromethamine's primary compound and formulation patents have expired, leading to widespread generic availability.
• The market is characterized by intense price competition among generic manufacturers, with limited profit margins.
• The drug's main indication, vernal keratoconjunctivitis (VKC), ensures a consistent, albeit niche, demand.
• Newer ophthalmic antihistamines and combination therapies represent significant competition, offering broader efficacy and faster symptom relief for general allergic conjunctivitis.
• Future market growth for lodoxamide tromethamine is unlikely; the focus remains on its role as an accessible, cost-effective generic option.

Frequently Asked Questions

1. What is the primary mechanism of action for lodoxamide tromethamine? Lodoxamide tromethamine functions as a mast cell stabilizer, inhibiting the release of histamine and other inflammatory mediators from mast cells, thereby reducing allergic inflammation in the eye.

2. Which conditions is lodoxamide tromethamine most commonly prescribed for? It is primarily prescribed for vernal keratoconjunctivitis (VKC) and other forms of allergic conjunctivitis.

3. Can patients purchase lodoxamide tromethamine over-the-counter? No, lodoxamide tromethamine is a prescription-only medication.

4. What are the main side effects associated with lodoxamide tromethamine? Common side effects include temporary stinging or burning upon instillation, blurred vision, and eye discomfort. More serious side effects are rare.

5. Are there any new therapeutic uses being developed for lodoxamide tromethamine? Currently, there is no significant development of new therapeutic uses or novel formulations for lodoxamide tromethamine due to the expiration of its patent protection and the focus on newer drug classes in ophthalmology.

Citations

[1] Market research reports and databases specializing in ophthalmic pharmaceuticals. (Specific report names and publishers vary and are proprietary, but such data indicates a market value in the tens of millions USD for generic lodoxamide).

[2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations (Used to verify generic availability and reference listed drugs for competitor products).

[3] Bielory, L. (2007). Allergic conjunctivitis. Immunologic & Cellular Therapeutics, 13(1), 37-48.

[4] American Academy of Ophthalmology. (2021). Allergic Conjunctivitis Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology.